Trial Profile
Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2016
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Insulin aspart/insulin protamine aspart
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca; Bristol-Myers Squibb